Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. (Q54290362)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Benjamin Yip

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Kevin Chaung

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Huy N Trinh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Huy A Nguyen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Aijaz Ahmed

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Ramsey Cheung

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Mindie H Nguyen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

26 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

3011-3016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10620-012-2402-2

9 March 2020

exact match

0 references

cites work

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Antiviral drug resistance: clinical consequences and molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

High rate of complete viral suppression with combination therapy in patients with chronic hepatitis B and prior treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-012-2402-2

10.1007/S10620-012-2402-2

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23010744%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference